Inhaled nitric oxide for reducing major adverse events requiring intensive life support in adults undergoing cardiac surgery with cardiopulmonary bypass: protocol for a phase III, double-blind, multicenter randomized controlled trial (NORISC Trial)
Nitric Oxide · 2026
DOI: 10.1016/j.niox.2026.06.005 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nitric Oxide, 2026. Verfasst von Lini Wang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Perioperative Medicine, Key Laboratory of Anesthesiology (The Fourth Military Medical University), Ministry of Educa…. Hauptthemen laut MEDLINE: Cardiopulmonary Bypass, Nitric Oxide, Cardiac Surgical Procedures, Postoperative Complications. Die Arbeit nennt 36 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
INTRODUCTION: Cardiac surgery remains a high-risk intervention, with postoperative complications, including ischemic events (myocardial infarction and stroke), acute kidney injury, respiratory failure, and neurocognitive dysfunction, affecting up to 30% of patients and resulting in increased mortality. While inhaled nitric oxide (NO) is traditionally used for pulmonary hypertension and right ventricular dysfunction, recent experimental and clinical studies suggest its organ-protective potential may mitigate ischemia-reperfusion injury and hemolysis induced toxicity. However, whether these physiological and mechanistic effects translate into improved patient-centered outcomes remains unproven in a large-scale setting. The NORISC trial aims to determine whether perioperative NO administration reduces major complications requiring intensive life support following cardiac surgery. METHOD AND ANALYSIS: This is an international, multicenter, double-blind, randomized (1:1), parallel-arm superiority trial. We will enroll 3650 patients undergoing elective cardiac surgery with cardiopulmonary bypass (CPB). The intervention group will receive NO at 80 parts per million (ppm) via the oxygenator sweep gas during CPB, followed by inhaled NO at 40-80 ppm via mechanical ventilation for up to 6 h postoperatively or until extubation, whichever occurs first. The control group will receive standard care with placebo gas. The primary outcome is a 30-d composite of all-cause mortality and major adverse events (MAEs) necessitating intensive life support (e.g., stage 3 AKI, mechanical circulatory support, or prolonged ventilation, etc). Based on a hypothesized 20% relative risk reduction (from 20% to 16%), a sample size of 3650 provides 80% power at a one-sided α of 0.025. Conclusion/Expected Impact: The NORISC trial will provide high-quality, definitive evidence on the clinical efficacy of NO in cardiac surgery. By targeting hemolysis-mediated organ injury through a standardized delivery strategy, this study has the potential to redefine perioperative management and reduce the global burden of postoperative morbidity. ETHICS AND DISSEMINATION: The protocol has received Institutional Review Board approval at all participating centers. Recruitment commenced in May 2025. Results will be disseminated through peer-reviewed publications and international scientific congresses. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT06702553.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Perioperative Medicine, Key Laboratory of Anesthesiology (The Fourth Military Medical University), Ministry of Education of China, Anesthesia Clinical Research Center, Xijing Hospital, T…
- Laboratory of Critical Care Medicine, Department of Anesthesiology and Intensive Care Medicine, Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 111a Kievskaya St., Tom…
- Department of Anesthesiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
- Scientific Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia.
- Department of Anesthesiology and Intensive Care, Meshalkin National Medical Research Center, Federal State Budgetary Institution National Medical Research Center Named After Academician E.N. Мeshalkin of the Ministry of…
- Tianjin University Chest Hospital, Tianjin Key Laboratory of Cardiovascular Emergency and Critical Care, Tianjin Municipal Science and Technology Bureau, Tianjin, 300222, China.
Zitieren
APA
Wang, L., Kamenshchikov, N. O., Zhang, H., Huang, M., Tyo, M. A., Кoyanidi, A. Y., Shi, J., Evgeny, G., Sergey, P., Zhang, Z., Yang, X., Gao, B., Boboshko, V., Moroz, G., Vasilev, M., Zhai, W., Min, J., Liu, Z., Wang, J., …, & Lei, C. (2026). Inhaled nitric oxide for reducing major adverse events requiring intensive life support in adults undergoing cardiac surgery with cardiopulmonary bypass: protocol for a phase III, double-blind, multicenter randomized controlled trial (NORISC Trial). Nitric Oxide. https://doi.org/10.1016/j.niox.2026.06.005
Vancouver
Wang L, Kamenshchikov NO, Zhang H, Huang M, Tyo MA, Кoyanidi AY, et al. Inhaled nitric oxide for reducing major adverse events requiring intensive life support in adults undergoing cardiac surgery with cardiopulmonary bypass: protocol for a phase III, double-blind, multicenter randomized controlled trial (NORISC Trial). Nitric Oxide. 2026. doi:10.1016/j.niox.2026.06.005
BibTeX
@article{Wang2026,
author = {Wang, Lini and Kamenshchikov, Nikolay O and Zhang, Hui and Huang, Manli and Tyo, Mark A and Кoyanidi, Alexander Y and Shi, Jing and Evgeny, Grigoryev and Sergey, Pogosov and Zhang, Zefei and Yang, Xue and Gao, Baobao and Boboshko, Vladimir and Moroz, Gleb and Vasilev, Mikhail and Zhai, Wenqian and Min, Jia and Liu, Zhiyi and Wang, Jiawan and Miao, Zi Hao and Wu, Qingping and Song, Zongbing and Berra, Lorenzo and Lei, Chong},
title = {Inhaled nitric oxide for reducing major adverse events requiring intensive life support in adults undergoing cardiac surgery with cardiopulmonary bypass: protocol for a phase III, double-blind, multicenter randomized controlled trial (NORISC Trial)},
journal = {Nitric Oxide},
year = {2026},
doi = {10.1016/j.niox.2026.06.005}
}
EUVIMED